{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-005898","form_type":"8-K","ticker":"PETV","cik":"0001512922","company_name":"PetVivo Holdings, Inc.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.437678+00:00","generated_at":"2026-06-06T04:15:46.758331+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PetVivo Q3 revenue up 17% YoY to $596K; net loss narrows to $1.75M","bullets":["Revenue $595,891 vs $510,109 YoY; new Covetrus distribution contributed $106K, MWI sales $440K.","Net loss $1,749,848 ($0.12 per share) vs $2,311,618 ($0.23) prior year; gain on extinguishment of payables.","Operating loss $2,133,624 vs $2,318,818; operating expenses flat at $2.55M.","Raised $1.2M in gross proceeds from private offering after quarter end.","Added Diane Levitan, DVM, to board; signed distribution deals with Covetrus and MWV."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-005898","json":"https://secwatch.observer/filing/0001493152-24-005898.json","markdown":"https://secwatch.observer/filing/0001493152-24-005898.md","text":"https://secwatch.observer/filing/0001493152-24-005898.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512922/000149315224005898/0001493152-24-005898-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512922/000149315224005898/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:15:46.758331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"df369c535575b1deb0501b9447ba0ea86f1d4b1d","claim":"PetVivo Holdings, Inc. reported the three months ended December 31, 2023 results: revenue $595,891, net income ($0.12) per share, EPS ($0.12) per share.","evidence_excerpt":"Third Quarter Financial Results For The Three Months Ended December 31, 2023 Compared to The Three Months Ended December 31, 2022 Total Revenues . Revenues were $595,891 and $510,109 for three months ended December 31, 2023 and 2022, respectively. Revenues in the three months ended December 31, 2023 consist of sales of our SpryngTM product to MWI","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512922/000149315224005898/0001493152-24-005898-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Revenue","value":"$595,891"},{"label":"Net income","value":"($0.12) per share"},{"label":"EPS","value":"($0.12) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}